Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin

Talha Badar, Mehdi Hamadani, Veronika Bachanova, Kami J. Maddocks, Elvira Umyarova, Julio C. Chavez, Narendranath Epperla, Saurabh Chhabra, Ana C. Xavier, Reem Karmali, Mohammed Salhab, Nishitha Reddy, Martha J. Glenn, Francisco J. Hernandez-Ilizaliturri, Christopher R. Flowers, Andrew Evens, Zheng Zhou, Frederick Lansigan, Stefan K. Barta, Jonathon B. CohenTimothy S. Fenske, Luciano J. Costa

Research output: Contribution to journalArticle

Abstract

We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in group B (n = 197) received ifosfamide, carboplatin, and etoposide (ICE) +/− rituximab. No difference in overall response rates (CR + PR) was observed based on salvage chemotherapy regimen and COO. After adjustment for the presence of ultra high-risk features, overall survival of germinal center B-cell like (GCB) DLBCL patients in group A was not significantly different from survival in group B (HR 0.86, 95% CI 0.46–1.60, p =.64). Similarly, within non-GCB DLBCL cohort, survival in group A was comparable to group B (HR 0.53, 95% CI 0.20–1.44, p =.21). We did not find an outcome difference between two commonly used salvage chemotherapy regimens in patients with PTF DLBCL based on COO.

Original languageEnglish (US)
Pages (from-to)940-946
Number of pages7
JournalLeukemia and Lymphoma
Volume60
Issue number4
DOIs
StatePublished - Mar 21 2019

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Treatment Failure
Drug Therapy
B-Lymphocytes
Ifosfamide
Germinal Center
Survival
Carboplatin
Cytarabine
Etoposide

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Keywords

  • Refractory diffuse large B-cell lymphoma
  • germinal center B-cell like DLBCL
  • putative cell-of-origin

Cite this

Badar, Talha ; Hamadani, Mehdi ; Bachanova, Veronika ; Maddocks, Kami J. ; Umyarova, Elvira ; Chavez, Julio C. ; Epperla, Narendranath ; Chhabra, Saurabh ; Xavier, Ana C. ; Karmali, Reem ; Salhab, Mohammed ; Reddy, Nishitha ; Glenn, Martha J. ; Hernandez-Ilizaliturri, Francisco J. ; Flowers, Christopher R. ; Evens, Andrew ; Zhou, Zheng ; Lansigan, Frederick ; Barta, Stefan K. ; Cohen, Jonathon B. ; Fenske, Timothy S. ; Costa, Luciano J. / Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. In: Leukemia and Lymphoma. 2019 ; Vol. 60, No. 4. pp. 940-946.
@article{77650eaeaa684b4db697c4851f13f865,
title = "Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin",
abstract = "We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in group B (n = 197) received ifosfamide, carboplatin, and etoposide (ICE) +/− rituximab. No difference in overall response rates (CR + PR) was observed based on salvage chemotherapy regimen and COO. After adjustment for the presence of ultra high-risk features, overall survival of germinal center B-cell like (GCB) DLBCL patients in group A was not significantly different from survival in group B (HR 0.86, 95{\%} CI 0.46–1.60, p =.64). Similarly, within non-GCB DLBCL cohort, survival in group A was comparable to group B (HR 0.53, 95{\%} CI 0.20–1.44, p =.21). We did not find an outcome difference between two commonly used salvage chemotherapy regimens in patients with PTF DLBCL based on COO.",
keywords = "Refractory diffuse large B-cell lymphoma, germinal center B-cell like DLBCL, putative cell-of-origin",
author = "Talha Badar and Mehdi Hamadani and Veronika Bachanova and Maddocks, {Kami J.} and Elvira Umyarova and Chavez, {Julio C.} and Narendranath Epperla and Saurabh Chhabra and Xavier, {Ana C.} and Reem Karmali and Mohammed Salhab and Nishitha Reddy and Glenn, {Martha J.} and Hernandez-Ilizaliturri, {Francisco J.} and Flowers, {Christopher R.} and Andrew Evens and Zheng Zhou and Frederick Lansigan and Barta, {Stefan K.} and Cohen, {Jonathon B.} and Fenske, {Timothy S.} and Costa, {Luciano J.}",
year = "2019",
month = "3",
day = "21",
doi = "10.1080/10428194.2018.1515944",
language = "English (US)",
volume = "60",
pages = "940--946",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

Badar, T, Hamadani, M, Bachanova, V, Maddocks, KJ, Umyarova, E, Chavez, JC, Epperla, N, Chhabra, S, Xavier, AC, Karmali, R, Salhab, M, Reddy, N, Glenn, MJ, Hernandez-Ilizaliturri, FJ, Flowers, CR, Evens, A, Zhou, Z, Lansigan, F, Barta, SK, Cohen, JB, Fenske, TS & Costa, LJ 2019, 'Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin', Leukemia and Lymphoma, vol. 60, no. 4, pp. 940-946. https://doi.org/10.1080/10428194.2018.1515944

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. / Badar, Talha; Hamadani, Mehdi; Bachanova, Veronika; Maddocks, Kami J.; Umyarova, Elvira; Chavez, Julio C.; Epperla, Narendranath; Chhabra, Saurabh; Xavier, Ana C.; Karmali, Reem; Salhab, Mohammed; Reddy, Nishitha; Glenn, Martha J.; Hernandez-Ilizaliturri, Francisco J.; Flowers, Christopher R.; Evens, Andrew; Zhou, Zheng; Lansigan, Frederick; Barta, Stefan K.; Cohen, Jonathon B.; Fenske, Timothy S.; Costa, Luciano J.

In: Leukemia and Lymphoma, Vol. 60, No. 4, 21.03.2019, p. 940-946.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin

AU - Badar, Talha

AU - Hamadani, Mehdi

AU - Bachanova, Veronika

AU - Maddocks, Kami J.

AU - Umyarova, Elvira

AU - Chavez, Julio C.

AU - Epperla, Narendranath

AU - Chhabra, Saurabh

AU - Xavier, Ana C.

AU - Karmali, Reem

AU - Salhab, Mohammed

AU - Reddy, Nishitha

AU - Glenn, Martha J.

AU - Hernandez-Ilizaliturri, Francisco J.

AU - Flowers, Christopher R.

AU - Evens, Andrew

AU - Zhou, Zheng

AU - Lansigan, Frederick

AU - Barta, Stefan K.

AU - Cohen, Jonathon B.

AU - Fenske, Timothy S.

AU - Costa, Luciano J.

PY - 2019/3/21

Y1 - 2019/3/21

N2 - We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in group B (n = 197) received ifosfamide, carboplatin, and etoposide (ICE) +/− rituximab. No difference in overall response rates (CR + PR) was observed based on salvage chemotherapy regimen and COO. After adjustment for the presence of ultra high-risk features, overall survival of germinal center B-cell like (GCB) DLBCL patients in group A was not significantly different from survival in group B (HR 0.86, 95% CI 0.46–1.60, p =.64). Similarly, within non-GCB DLBCL cohort, survival in group A was comparable to group B (HR 0.53, 95% CI 0.20–1.44, p =.21). We did not find an outcome difference between two commonly used salvage chemotherapy regimens in patients with PTF DLBCL based on COO.

AB - We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in group B (n = 197) received ifosfamide, carboplatin, and etoposide (ICE) +/− rituximab. No difference in overall response rates (CR + PR) was observed based on salvage chemotherapy regimen and COO. After adjustment for the presence of ultra high-risk features, overall survival of germinal center B-cell like (GCB) DLBCL patients in group A was not significantly different from survival in group B (HR 0.86, 95% CI 0.46–1.60, p =.64). Similarly, within non-GCB DLBCL cohort, survival in group A was comparable to group B (HR 0.53, 95% CI 0.20–1.44, p =.21). We did not find an outcome difference between two commonly used salvage chemotherapy regimens in patients with PTF DLBCL based on COO.

KW - Refractory diffuse large B-cell lymphoma

KW - germinal center B-cell like DLBCL

KW - putative cell-of-origin

UR - http://www.scopus.com/inward/record.url?scp=85054414534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054414534&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1515944

DO - 10.1080/10428194.2018.1515944

M3 - Article

C2 - 30277110

AN - SCOPUS:85054414534

VL - 60

SP - 940

EP - 946

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -